logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
25/05/2026
The S&P/TSX Composite Index of the Toronto Stock Exchange opened up 164.45 points, or 0.48%, at 34,635.81 points.
Latest
3 m ago
Li Qiang Meets with Serbian President Vucic
3 m ago
Jinhe Business Management: Clarification Announcement on Rumors of Lawsuit with Water Vapor Stone
4 m ago
Wuhan Research Institute of Technology (300550.SZ): Planning for changes in controlling ownership matters. Stock trading halted.
5 m ago
The "Private Enterprise Entering the Border" initiative has signed a total of 132 projects in Dandong, Liaoning.
6 m ago
US pharmaceutical company LLY.N announced that its experimental gene editing therapy for treating high cholesterol has shown positive results in a Phase 1b clinical trial. The company stated that in the Phase 1b study aimed at adults with heterozygous familial hypercholesterolemia or early-onset coronary artery disease, a single administration of the therapy called Verve-102 resulted in a reduction of PCSK9 protein levels by up to 88% and a decrease in low-density lipoprotein cholesterol by up to 62%. The therapy utilizes in vivo base editing technology to effectively shut down the PCSK9 gene in the liver, mimicking a natural genetic variation that can prevent heart disease. The US Food and Drug Administration (FDA) has granted fast track designation to the therapy. LLY.N reported that the therapy has a duration of effect lasting up to 18 months and no serious adverse events related to the treatment have been reported. The company plans to start Phase 2 clinical trials of Verve-102 by the end of this year.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.